Evidence map›Paper›PMID 30252536›Full record

ArticleFASEB journal : official publication of the Federation of American Societies for Experimental Biology2019

RARβ acts as both an upstream regulator and downstream effector of miR-22, which epigenetically regulates NUR77 to induce apoptosis of colon cancer cells.

Ying Hu, Samuel W French, Thinh Chau, Hui-Xin Liu, Lili Sheng, Fang Wei, Jesse Stondell, Juan C Garcia, Yanlei Du, Christopher L Bowlus and 1 more

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
1.2field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 32 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Controversy and multiple roles of the solitary nucleus receptor Nur77 in disease and physiology.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2025
    Review
  6. Article
  7. Article
  8. Review
  9. Review
  10. Review
  11. miR-22 gene therapy treats HCC by promoting anti-tumor immunity and enhancing metabolism.Molecular therapy : the journal of the American Society of Gene Therapy · 2023
    Article
  12. Review
  13. Article
  14. Article
  15. Review
  16. Reposition of the anti-inflammatory drug diacerein in anSaudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2022
    Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 6 institutions in 2 countries.

Ying HuDepartment of Medical Pathology and Laboratory Medicine, University of California, Davis Health System, Sacramento, California, USA.
Samuel W FrenchDepartment of Pathology and Laboratory Medicine, University of California, Los Angeles, Los Angeles, California, USA.
Thinh ChauDepartment of Medical Pathology and Laboratory Medicine, University of California, Davis Health System, Sacramento, California, USA.
Hui-Xin LiuDepartment of Medical Pathology and Laboratory Medicine, University of California, Davis Health System, Sacramento, California, USA.
Lili ShengDepartment of Medical Pathology and Laboratory Medicine, University of California, Davis Health System, Sacramento, California, USA.
Fang WeiDepartment of Gastroenterology and Hepatology, First Municipal People's Hospital of Guangzhou, Guangzhou Medical College, Guangzhou, China.
Jesse StondellDivision of Gastroenterology, University of California, Davis Health System, Sacramento, California, USA.
Juan C GarciaDivision of Gastroenterology, University of California, Davis Health System, Sacramento, California, USA.
Yanlei DuDepartment of Gastroenterology and Hepatology, First Municipal People's Hospital of Guangzhou, Guangzhou Medical College, Guangzhou, China.
Christopher L BowlusDivision of Gastroenterology, University of California, Davis Health System, Sacramento, California, USA.
Yu-Jui Yvonne WanDepartment of Medical Pathology and Laboratory Medicine, University of California, Davis Health System, Sacramento, California, USA.
University of California, Davis · USUC Davis Health · USGuangzhou First People's Hospital · CNGuangzhou Medical University · CNUniversity of California Davis Medical Center · USUniversity of California, Los Angeles · US

Funding

The Role of Probiotic Bifidobacteria and Bile Acid Metabolism in CarcinogenesisU01CA179582 · NCI · UNIVERSITY OF CALIFORNIA AT DAVIS · PI MILLS, DAVID ANDREW, SLUPSKY, CAROLYN · 2014 to 2018
$2.8M
Liver Cancer Therapy by MiR-22 and Its InducersR01CA222490 · NCI · UNIVERSITY OF CALIFORNIA AT DAVIS · PI WAN, YU-JUI YVONNE · 2018 to 2023
$2.1M
NCI NIH HHS R01 CA222490NCI NIH HHS U01 CA179582
6 · The paper itself

Abstract

This study investigates the mechanism and consequences of microRNA-22 ( miR-22) induction. Our data revealed for the first time that retinoic acid (RA) and histone deacetylase (HDAC) inhibitors, including short-chain fatty acids and suberanilohydroxamic acid (SAHA), could individually or in combination induce miR-22. This induction was mediated via RA receptor β (RARβ) binding to a direct repeat 5 (DR5) motif. In addition, we uncovered HDAC1 as a novel miR-22 target. In an miR-22-dependent manner, HDAC inhibitors and RA reduced HDAC1, HDAC4, and sirtuin 1 (SIRT1), which were involved in chromatin remodeling of the RARβ and nerve growth factor IB ( NUR77). Thus, HDAC inhibitors and RA-induced miR-22 resulted in simultaneous induction of cytoplasmic RARβ and NUR77, leading to apoptosis of colon cancer cells. In mice, miR-22 and its inducers inhibited the growth of xenograft colon cancer. Moreover, tumor size reduction was accompanied by elevated miR-22, NUR77, and RARβ and by reduced HDACs. In human colon polyps and adenocarcinomas, miR-22 and RARβ were consistently reduced, which was associated with elevated HDAC1, HDAC4, and SIRT1 in colon adenocarcinomas. Results from this study revealed a novel anticancer mechanism of RARβ via miR-22 induction to epigenetically regulate itself and NUR77, providing a promising cancer treatment modality using miR-22 and its inducers.-Hu, Y., French, S. W., Chau, T., Liu, H.-X., Sheng, L., Wei, F., Stondell, J., Garcia, J. C., Du, Y., Bowlus, C. L., Wan, Y.-J. Y. RARβ acts as both an upstream regulator and downstream effector of miR-22, which epigenetically regulates NUR77 to induce apoptosis of colon cancer cells.

Indexed as

AdenocarcinomaAnimalsApoptosisCell Line, TumorColonic NeoplasmsEpigenesis, GeneticGene Expression Regulation, NeoplasticGene SilencingHeterograftsHistone Deacetylase 1Histone Deacetylase InhibitorsHumansMiceMicroRNAsNuclear Receptor Subfamily 4, Group A, Member 1Receptors, Retinoic AcidHDAC1 protein, humanHistone Deacetylase 1Histone Deacetylase InhibitorsMicroRNAsMIRN22 microRNA, humanNR4A1 protein, humanNuclear Receptor Subfamily 4, Group A, Member 1Receptors, Retinoic Acidretinoic acid receptor betaTretinoinbutyratenuclear receptorpropionateprotein deacetylaseshort-chain fatty acid

Identifiers

PMID30252536
PMCPMC6338632
OpenAlexW2892555207

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.